CoChat

Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?

Open access
Turna, Jasmine, Patterson, Beth, Van Ameringen, Michael · 2017 · Depression and Anxiety
Cited by 100

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Anxiety and related disorders are the most common mental conditions affecting the North American population. Despite their established efficacy, first-line antidepressant treatments are associated with significant side effects, leading many afflicted individuals to seek alternative treatments. Cannabis is commonly viewed as a natural alternative for a variety of medical and mental health conditions. Currently, anxiety ranks among the top five medical symptoms for which North Americans report using medical marijuana. However, upon careful review of the extant treatment literature, the anxiolytic effects of cannabis in clinical populations are surprisingly not well-documented. The effects of cannabis on anxiety and mood symptoms have been examined in healthy populations and in several small studies of synthetic cannabinoid agents but there are currently no studies which have examined the effects of the cannabis plant on anxiety and related disorders. In light of the rapidly shifting landscape regarding the legalization of cannabis for medical and recreational purposes, it is important to highlight the significant disconnect between the scientific literature, public opinion, and related policies. The aim of this article is to provide a comprehensive review of the current cannabis treatment literature, and to identify the potential for cannabis to be used as a therapeutic intervention for anxiety, mood, and related disorders. Searches of five electronic databases were conducted (PubMed, MEDLINE, Web of Science, PsychINFO, and Google Scholar), with the most recent in February 2017. The effects of cannabis on healthy populations and clinical psychiatric samples will be discussed, focusing primarily on anxiety and mood disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.22664

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 77

  1. Ablon, 1974, High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients, American Journal of Psychiatry, 131, 448, 10.1176/ajp.1974.131.4.448 · DOI
  2. Ashton, 1981, The seed and the soil: Effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man, British Journal of Clinical Pharmacology, 12, 705, 10.1111/j.1365-2125.1981.tb01294.x · DOI · Paper page
  3. Aso, 2011, Genes differentially expressed in CB 1 knockout mice: Involvement in the depressive-like phenotype, European Neuropsychopharmacology, 21, 11, 10.1016/j.euroneuro.2010.06.007 · DOI
  4. Bandelow, 2008, World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-First revision, World Journal of Biological Psychiatry, 9, 248, 10.1080/15622970802465807 · DOI · Paper page
  5. Bhattacharyya, 2010, Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, Neuropsychopharmacology, 35, 764, 10.1038/npp.2009.184 · DOI · Paper page
  6. Blass, 2008, Treating depression with cannabinoids (Cannabinoids 3)
  7. Blessing, 2015, Cannabidiol as a potential treatment for anxiety disorders, Neurotherapeutics, 12, 825, 10.1007/s13311-015-0387-1 · DOI · Paper page
  8. Bonn-Miller, 2014, Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD, Drug and alcohol Dependence, 136, 162, 10.1016/j.drugalcdep.2013.12.008 · DOI · Paper page
  9. Bonn-Miller, 2007, Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers, Addictive Behaviors, 32, 49, 10.1016/j.addbeh.2006.03.018 · DOI · Paper page
  10. Bossong, 2013, The endocannabinoid system and emotional processing: A pharmacological fMRI study with∆ 9-tetrahydrocannabinol, European Neuropsychopharmacology, 23, 1687, 10.1016/j.euroneuro.2013.06.009 · DOI
  11. Cameron, 2014, Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation, Journal of Clinical Psychopharmacology, 34, 559, 10.1097/JCP.0000000000000180 · DOI · Paper page
  12. Cerdá, 2012, Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence, Drug and Alcohol Dependence, 120, 22, 10.1016/j.drugalcdep.2011.06.011 · DOI · Paper page
  13. Cheung, 2010, Anxiety and mood disorders and cannabis use, American Journal of Drug and Alcohol Abuse, 36, 118, 10.3109/00952991003713784 · DOI · Paper page
  14. Cooper, 2013, Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers, Neuropsychopharmacology, 38, 1984, 10.1038/npp.2013.97 · DOI
  15. Cougle, 2011, Posttraumatic stress disorder and cannabis use in a nationally representative sample, Psychology of Addictive Behaviors, 25, 554, 10.1037/a0023076 · DOI · Paper page
  16. Crippa, 2009, Cannabis and anxiety: A critical review of the evidence, Human Psychopharmacology: Clinical and Experimental, 24, 515, 10.1002/hup.1048 · DOI · Paper page
  17. Das, 2013, Cannabidiol enhances consolidation of explicit fear extinction in humans, Psychopharmacology, 226, 781, 10.1007/s00213-012-2955-y · DOI · Paper page
  18. Degenhardt, 2012, Extent of illicit drug use and dependence, and their contribution to the global burden of disease, Lancet, 379, 55, 10.1016/S0140-6736(11)61138-0 · DOI · Paper page
  19. Downey, 2013, The effects of cannabis and alcohol on simulated driving: Influences of dose and experience, Accident Analysis and Prevention, 50, 879, 10.1016/j.aap.2012.07.016 · DOI · Paper page
  20. D'Souza, 2004, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis, Neuropsychopharmacology, 29, 1558, 10.1038/sj.npp.1300496 · DOI · Paper page
  21. D'souza, 2015, Medical marijuana: Is the cart before the horse, JAMA, 313, 2431, 10.1001/jama.2015.6407 · DOI
  22. Feingold, 2015, The association between cannabis use and mood disorders: A longitudinal study, Journal of Affective Disorders, 172, 211, 10.1016/j.jad.2014.10.006 · DOI · Paper page
  23. Fusar-Poli, 2009, S39-01 Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing, European Psychiatry, 24, S206, 10.1016/S0924-9338(09)70439-0 · DOI
  24. Gates, 2014, The effects of cannabinoid administration on sleep: A systematic review of human studies, Sleep Medicine Reviews, 18, 477, 10.1016/j.smrv.2014.02.005 · DOI
  25. Gibbs, 2015, Cannabis use and mania symptoms: A systematic review and meta-analysis, Journal of Affective Disorders, 171, 39, 10.1016/j.jad.2014.09.016 · DOI · Paper page
  26. Glass, 1981, Single-dose study of nabilone in anxious volunteers, Journal of Clinical Pharmacology, 21, 383S, 10.1002/j.1552-4604.1981.tb02618.x · DOI · Paper page
  27. Gomes, 2011, Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 434, 10.1016/j.pnpbp.2010.11.027 · DOI
  28. Gorzalka, 2011, Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 1575, 10.1016/j.pnpbp.2010.11.021 · DOI
  29. Grant, 2011, Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: A pilot study, Psychopharmacology, 218, 493, 10.1007/s00213-011-2347-8 · DOI
  30. Grant, 2016, Associations of posttraumatic stress disorder symptoms with marijuana and synthetic cannabis use among young adult US Veterans: A pilot investigation, Journal of Studies on Alcohol and Drugs, 77, 509, 10.15288/jsad.2016.77.509 · DOI
  31. Greer, 2014, PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program, Journal of Psychoactive Drugs, 46, 73, 10.1080/02791072.2013.873843 · DOI · Paper page
  32. Grotenhermen, 2003, Pharmacokinetics and pharmacodynamics of cannabinoids, Clinical Pharmacokinetics, 42, 327, 10.2165/00003088-200342040-00003 · DOI · Paper page
  33. Gruber, 1996, Do patients use marijuana as an antidepressant, Depression, 4, 77, 10.1002/(SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.0.CO;2-C · DOI · Paper page
  34. Gruber, 2012, Marijuana impacts mood in bipolar disorder: A pilot study, Mental Health and Substance Use, 5, 228, 10.1080/17523281.2012.659751 · DOI
  35. Hasin, 2015, Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: Results from annual, repeated cross-sectional surveys, Lancet Psychiatry, 2, 601, 10.1016/S2215-0366(15)00217-5 · DOI · Paper page
  36. Hemming, 1993, Effective treatment of Tourette's syndrome with marijuana, Journal of Psychopharmacology, 7, 389, 10.1177/026988119300700411 · DOI · Paper page
  37. Henquet, 2006, Cannabis use and expression of mania in the general population, Journal of Affective Disorders, 95, 103
  38. Ilaria, 1981, Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis, Current Therapeutic Research, Clinical and Experimental, 29, 943
  39. Jetly, 2015, The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study, Psychoneuroendocrinology, 51, 585, 10.1016/j.psyneuen.2014.11.002 · DOI · Paper page
  40. Johnson, 2016, Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD, Journal of Affective Disorders, 190, 439, 10.1016/j.jad.2015.10.048 · DOI
  41. Karniol, 1974, Cannabidiol interferes with the effects of Δ 9-tetrahydrocannabinol in man, European Journal of Pharmacology, 28, 172, 10.1016/0014-2999(74)90129-0 · DOI · Paper page
  42. Kessler, 2005, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication, Archives of General Psychiatry, 62, 593, 10.1001/archpsyc.62.6.593 · DOI · Paper page
  43. Kevorkian, 2015, Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample, Psychology of addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors, 29, 633, 10.1037/adb0000110 · DOI
  44. Kotin, 1973, Δ9-Tetrahydrocannabinol in depressed patients, Archives of General Psychiatry, 28, 345, 10.1001/archpsyc.1973.01750330041007 · DOI · Paper page
  45. Ksir, 2016, Cannabis and psychosis: A critical overview of the relationship, Current Psychiatry Reports, 18, 1, 10.1007/s11920-015-0657-y · DOI · Paper page
  46. Lee, 2009, Anxiolytic effect of an oral cannabinoid in patients with anxiety, European Journal of Pain, 13, S200
  47. Lin, 2016, Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample, Addictive Behaviors, 61, 99, 10.1016/j.addbeh.2016.05.015 · DOI · Paper page
  48. Machado Rocha, 2008, Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis, European Journal of Cancer Care, 17, 431, 10.1111/j.1365-2354.2008.00917.x · DOI · Paper page
  49. Martín-Sánchez, 2009, Systematic review and meta-analysis of cannabis treatment for chronic pain, Pain Medicine, 10, 1353, 10.1111/j.1526-4637.2009.00703.x · DOI · Paper page
  50. Martin-Santos, 2012, Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers, Current Pharmaceutical Design, 18, 4966, 10.2174/138161212802884780 · DOI · Paper page
  51. Martyn, 1995, Nabilone in the treatment of multiple sclerosis, Lancet, 345, 579, 10.1016/S0140-6736(95)90485-9 · DOI
  52. Mashiah, 2012, Medical cannabis as treatment for chronic combat PTSD: Promising results in an open label pilot study
  53. Müller-Vahl, 1998, Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome, Acta Psychiatrica Scandinavica, 98, 502, 10.1111/j.1600-0447.1998.tb10127.x · DOI · Paper page
  54. Muller-Vahl, 1999, Treatment of tourette's syndrome with delta-9-tetrahydrocannbinol, American Journal of Psychiatry, 156, 495, 10.1176/ajp.156.3.495 · DOI
  55. National Academies of Sciences, Engineering, and Medicine, 2017, The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research, 289
  56. Passie, 2012, Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence, Drug Testing and Analysis, 4, 649, 10.1002/dta.1377 · DOI · Paper page
  57. Phillips, 2010, Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials, PLoS One, 5, e14433, 10.1371/journal.pone.0014433 · DOI · Paper page
  58. Pond, 1948, Psychological effects in depressive patients of the marihuana homologue synhexyl, Journal of Neurology, Neurosurgery and Psychiatry, 11, 271, 10.1136/jnnp.11.4.271 · DOI
  59. Rabinak, 2014, Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans, Neurobiology of Learning and Memory, 113, 125, 10.1016/j.nlm.2013.09.009 · DOI · Paper page
  60. Regelson, 1976, The Pharmacology of Marihuana, 763
  61. Reinarman, 2011, Who are medical marijuana patients? Population characteristics from nine California assessment clinics, Journal of Psychoactive Drugs, 43, 128, 10.1080/02791072.2011.587700 · DOI · Paper page
  62. Reznik , I. 2011 Medical cannabis use in post-traumatic stress disorder: A naturalistic observational study Abstract presented at the cannabinoid conference. Bonn, Germany 8 10
  63. Roitman, 2014, Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder, Clinical Drug Investigation, 34, 587, 10.1007/s40261-014-0212-3 · DOI · Paper page
  64. Roy-Byrne, 2015, Are medical marijuana users different from recreational users? The view from primary care, American Journal on Addictions, 24, 599, 10.1111/ajad.12270 · DOI
  65. Sandyk, 1988, Marijuana and Tourette's syndrome, Journal of Clinical Psychopharmacology, 8, 444, 10.1097/00004714-198812000-00021 · DOI
  66. Schindler, 2008, Improvement in refractory obsessive compulsive disorder with dronabinol, American Journal of Psychiatry, 165, 536, 10.1176/appi.ajp.2007.07061016 · DOI
  67. Sethi, 1986, Antianxiety effect of cannabis: Involvement of central benzodiazepine receptors, Biological Psychiatry, 21, 3, 10.1016/0006-3223(86)90003-X · DOI
  68. Stockings, 1947, A new euphoriant for depressive mental states, British Medical Journal, 1, 918, 10.1136/bmj.1.4512.918 · doi:10.1136/bmj.1.4512.918
  69. Swift, 2013, Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile, PloS one, 8, e70052, 10.1371/journal.pone.0070052 · DOI · Paper page
  70. Thomas, 2007, Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, British Journal of Pharmacology, 150, 613, 10.1038/sj.bjp.0707133 · DOI · Paper page
  71. Valverde, 2012, CB1 receptor-deficient mice as a model for depression, Neuroscience, 204, 193, 10.1016/j.neuroscience.2011.09.031 · DOI
  72. Volkow, 2014, Adverse health effects of marijuana use, New England Journal of Medicine, 370, 2219, 10.1056/NEJMra1402309 · DOI · Paper page
  73. Wade, 2003, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, Clinical Rehabilitation, 17, 21, 10.1191/0269215503cr581oa · DOI · Paper page
  74. Wall, 2011, Adolescent marijuana use from 2002 to 2008: Higher in states with medical marijuana laws, cause still unclear, Annals of Epidemiology, 21, 714, 10.1016/j.annepidem.2011.06.001 · DOI · Paper page
  75. Walsh, 2013, Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use, International Journal of Drug Policy, 24, 511, 10.1016/j.drugpo.2013.08.010 · DOI · Paper page
  76. Walsh, 2017, Medical cannabis and mental health: A guided systematic review, Clinical Psychology Review, 51, 15, 10.1016/j.cpr.2016.10.002 · DOI · Paper page
  77. Zuardi, 1982, Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects, Psychopharmacology, 76, 245, 10.1007/BF00432554 · DOI · Paper page

Cited by

Metadata

Authors
Turna, J., Patterson, B., & Van Ameringen, M.
Venue
Depression and Anxiety
Publisher
Wiley
Published
2017-06-21
Volume
34
Issue
11
Pages
1006-1017
ISSN
1091-4269 (ISSN-L)
OpenAlex
W2706778363
Cited by
100
References
29
FWCI
5.89
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.